New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.78%, which has investors questioning if this is right time to ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Wells Fargo notes that Summit Therapeutics (SMMT) partner Akeso (AKESF) received approval from China’s NMPA for ivonescimab as a monotherapy ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Janux Therapeutics, Inc.’s JANX share price has dipped by 5.83%, which has investors questioning if this is right time to buy.

Debiopharm further describes AbYlink as a one-step method that results in stable conjugation at defined and invariable sites on the Fc domain of an antibody, with no impact on antigen-binding regions, ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

Additionally, as previously announced, an oral presentation regarding Emi-Le will be given at the ESMO Breast Cancer 2025 ...

Prior screening mammography linked to earlier stage at breast cancer diagnosis, lower breast cancer mortality.